Hey guys, I attended the AGM, just some facts from the AGM:
1) The market for Phosgene derivatives in all is about 50,000 MT, whereas Phosgene Derivatives for Pharma Products are likely to be less than 20% of the total demand
2) Paushak has an annual capacity of approx. 3000MT which they may increase to 4000MT over the next 2-3 years (haven't chalked out any plans in particular).
@pjain Liked the write up. Thx. Can you pl compare RKFL with the other smaller peer - viz. MM forgings. They have marque clients in EU as well. Debt looks ok and valuations are cheaper. Of course, top line has been a bit flat last few qtrs but there is room for improvement. They came off a lower base and stabilising the expansion did a few quarters before. My guess is MMFL must be operating at about 75-80% util.
PS- got a small position in MMFL
Hi Nikhil,
W.R.T. your thoughts and my response, here is a far better articulation from my favourite Prof. on looking at valuations - the different metrics to apply when buying a stock and later when holding a stock - and when to execute sell decisions. I try to apply this framework to my investing.
http://www.safalniveshak.com/email-exchange-with-sanjay-bakshi-on-valuations/
Have a good weekend.
BR,
Aniket.
Aurobindo Pharma receives FDA Approval for Raloxifene Hydrochloride.
29 Aug 2015
Auro received the final approval from USFDAfor Raloxifene Hydrochloride Tablets 60mg.
It has estimated market size of US$404 Million for the twelve months ending June 2015 according to IMS.
This is the 45th ANDA to be approved out of Unit VII formulation facility in Hyderabad, India for
manufacturing Oral Non-Antibiotic products.It now has a total of 210 ANDA approvals.
Raloxifen.pdf (76.2 KB)
Thanks Mehnazfatima For Your Analysis ...Yesterday Md Of NIIT Was On Cnbc & Very Bullish on Their Skill Devlopment Area World Wide & They Are Very Confident Under Leadrship Of Mr Patwardhan Company Will Turn Around...
Thanks Mehnazfatima For Your Analysis ...Yesterday Md Of NIIT Was On Cnbc & Very Bullish on Their Skill Devlopment Area World Wide & They Are Very Confident Under Leadrship Of Mr Patwardhan Company Will Turn Around...
In stock market all time high level doesn't matter compare to which price u bought. It all depends on situation where you enter into that counter.
As Nifty down from 8300 to 7800 means Nifty P/E it self down from 24 - 22. So market relatively down all the stocks which reach to high valuation and normalize the fact with moderate growth for FY16
Now market is not in good mood to give high valuation for any stock. So its good time to enter and buy qlty stocks for 3-5 yrs horizon. There is no change in fundamental of Premco & it's business model.
Disc : I enter into emaco at 570 level
In stock market all time high level doesn't matter compare to which price u bought. It all depends on situation where you enter into that counter.
As Nifty down from 8300 to 7800 means Nifty P/E it self down from 24 - 22. So market relatively down all the stocks which reach to high valuation and normalize the fact with moderate growth for FY16
Now market is not in good mood to give high valuation for any stock. So its good time to enter and buy qlty stocks for 3-5 yrs horizon. There is no change in fundamental of Premco & it's business model.
Disc : I enter into emaco at 570 level
Please check my opening post regarding comparision to Vidhi. At this price, it's a good buy in my view. Stock had held quiet well in recent carnage.
Fy15 cash flow statement based on moneycontrol
Net Profit Before Tax 12.86
Net Cash From Operating Activities 7.50
Net Cash (used in)/from
Investing Activities -2.59
Net Cash (used in)/from Financing Activities -3.78
Net (decrease)/increase In Cash and Cash Equivalents 1.14
Opening Cash & Cash Equivalents 0.73
Closing Cash & Cash Equivalents 1.86
http://www.moneycontrol.com/financials/nglfinechem/cash-flow/NGL#NGL
Nothing is negative. It's 1.14 Cr